James Flickinger, OD
Optometrist · Scranton, PANPI 1184636284
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (35.8%), grants and food and beverage — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by AbbVie at 38.3% of the total. 2025 is the largest year on record at $5,245, 5.7 times the $921 reported in 2019. Among optometrist clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 147 payments — averaging $150.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$9K
- Glaukos Corporation$5K
- Coopervision Inc.$3K
- Biotissue Holdings Inc.$2K
- Bausch & Lomb Americas Inc.$966
- Alcon$904
- plus $2K from 12 others
What the payments were for
- Speaking & faculty fees$7,95036%
- Grants$6,25028%
- Travel & lodging$1,3736%
- Food & beverage$5,85326%
- Education$7503%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 12 | $8,504 |
| Glaukos Corporation | 5 | $4,538 |
| Coopervision Inc. | 22 | $3,087 |
| Biotissue Holdings Inc. | 25 | $1,970 |
| Bausch & Lomb Americas Inc. | 15 | $966 |
| Alcon | 29 | $904 |
| Sun Pharmaceutical Industries Inc. | 10 | $479 |
| Novartis | 6 | $299 |
| Oyster Point Pharma, Inc. | 5 | $283 |
| Kala Pharmaceuticals, Inc. | 3 | $256 |
| LKC Technologies, Inc. | 3 | $217 |
| Ocular Therapeutix, Inc. | 4 | $186 |
| Tarsus Pharmaceuticals, Inc. | 3 | $144 |
| Topcon Healthcare, Inc. | 1 | $136 |
| Mallinckrodt Enterprises LLC | 1 | $122 |
| Dompe US, Inc. | 1 | $56 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Tearlab Corp | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$7,000
- KXL System$3,250
- RESTASIS MULTIDOSE$2,750
- VUITY$2,250
- MyDay Contact Lens$2,200
- iStent infinite Trabecular Micro-Bypass System Model iS3$1,250
- iStent inject Trabecular Micro-Bypass System Model G2-M-IS$1,250
- iStent Infinite$1,250
- Travoprost Intraocular Implant - iDose$1,250
- ALPHAGAN P$1,000
- PHOTREXA CROSS-LINKING KIT$750
- XIIDRA$590
- MIEBO$476
- Prokera$300
- EYSUVIS$239
- INFUSE$237
- TYRVAYA$235
- CEQUA$226
- INVELTYS$137
- DEXTENZA$125
How this compares
$22,176 in reported general payments places this provider in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 84 | $115,587 |
| RestasisCyclosporine | 36 | $38,583 |
| CequaCyclosporine | 26 | $20,260 |
| Brimonidine Tartrate | 55 | $10,833 |
| VyzultaLatanoprostene Bunod | 17 | $6,536 |
| Travoprost | 16 | $5,038 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 11 | $4,230 |
| LumiganBimatoprost | 13 | $4,113 |
| TobradexTobramycin/Dexamethasone | 13 | $3,354 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 54 | $2,267 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,401 |
| Epinastine Hcl | 15 | $1,280 |
| Latanoprost | 138 | $1,254 |
| Prednisolone Acetate | 29 | $902 |
| Azithromycin | 16 | $68 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $966 | $122,123101 claims |
| AbbVieRestasis, Lumigan | $8,504 | $42,69649 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $479 | $20,26026 claims |
| AlconSimbrinza | $904 | $4,23011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,165 optometrist providers in Pennsylvania.
Other optometrist in Scranton
- Jennifer RandleScranton$24K
- Joseph ShovlinScranton$8K
- James DeomHazle Township$793K
- Gregory CaldwellDuncansville$547K
- Leslie O DellNew Freedom$388K
- Kevin BistlinePlymouth Meeting$302K
- Thomas KislanStroudsburg$266K
- Erick HendersonPittsburgh$266K
- Ryan YealyLancaster$164K
- Joseph SmayNew Kensington$147K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.